Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Panella

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|December 31, 2003
Sarcoma of mandibleEric R Carlson, Timothy Panella, Jon D Holmes
Thyroid : Official Journal of the American Thyroid Association|March 24, 2023
<i>Letter to the Editor: ETV6-NTRK2</i> Fusion Identified in a Patient with Medullary Thyroid CarcinomaOmar Alsharif, Timothy Panella, Laurentia Nodit, et al.
The Breast Journal|January 21, 2015
Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experienceAmila Orucevic, Jason Chen, James M McLoughlin, et al.
Cancers|August 13, 2015
Breast Cancer in Elderly Caucasian Women-An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall SurvivalAmila Orucevic, Matthew Curzon, Christina Curzon, et al.
The Breast Journal|December 18, 2012
Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian womenN Lynn Ferguson, John Bell, Robert Heidel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 20, 2024
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD studyOleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, et al.
Future Oncology (London, England)|May 7, 2025
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD studyOleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesotheliomaStanislaw M Mikulski, John J Costanzi, Nicholas J Vogelzang, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Future Oncology (London, England)|January 11, 2025
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinomaSoo J Park, David M Ellison, Ryan Weight, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|December 31, 2003
Sarcoma of mandibleEric R Carlson, Timothy Panella, Jon D Holmes
Thyroid : Official Journal of the American Thyroid Association|March 24, 2023
<i>Letter to the Editor: ETV6-NTRK2</i> Fusion Identified in a Patient with Medullary Thyroid CarcinomaOmar Alsharif, Timothy Panella, Laurentia Nodit, et al.
The Breast Journal|January 21, 2015
Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experienceAmila Orucevic, Jason Chen, James M McLoughlin, et al.
Cancers|August 13, 2015
Breast Cancer in Elderly Caucasian Women-An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall SurvivalAmila Orucevic, Matthew Curzon, Christina Curzon, et al.
The Breast Journal|December 18, 2012
Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian womenN Lynn Ferguson, John Bell, Robert Heidel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 20, 2024
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD studyOleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, et al.
Future Oncology (London, England)|May 7, 2025
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD studyOleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesotheliomaStanislaw M Mikulski, John J Costanzi, Nicholas J Vogelzang, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Future Oncology (London, England)|January 11, 2025
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinomaSoo J Park, David M Ellison, Ryan Weight, et al.
Pageof 2